Geneva, June 9 -- International Clinical Trials Registry received information related to the study (ACTRN12625000563460) titled 'Study to Evaluate the parameters of TRX-248 Transdermal System in Healthy Female Volunteers' on June 2.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Open (masking not used)
Assignment: Crossover
Type of endpoint: Pharmacokinetics
Primary Sponsor: Corsair Pharma, Inc.
Condition:
Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Cardiovascular - Hypertension
Intervention:
This is a Phase 1, open-label, placebo-controlled, crossover study evaluating the pharmacokinetics, safety, and tolerability of multiple formulations of the TRX...